Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9P298

UPID:
HIG1B_HUMAN

ALTERNATIVE NAMES:
Protein CLST 11240

ALTERNATIVE UPACC:
Q9P298; D3DX57; Q9P297

BACKGROUND:
Protein CLST 11240, recommended name HIG1 domain family member 1B, represents a pivotal area of study within biochemistry. The elucidation of its roles and the pathways it influences are critical for advancing our understanding of cellular function. This protein, with its distinct nomenclature, is at the forefront of research aimed at deciphering complex biological systems.

THERAPEUTIC SIGNIFICANCE:
Investigating HIG1 domain family member 1B's function offers a promising avenue for identifying new therapeutic approaches. As research progresses, the potential to uncover drug targets related to this protein increases, paving the way for innovative treatments that could benefit patients with conditions linked to its activity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.